News
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
Three upcoming posters, including an update on the ongoing Phase 1 trial of Calidi’s CLD-101 program, to be presented at the 2024 ASCO Annual Meeting
Presented new data on the mechanisms of action of Calidi’s new immunotherapies at the AACR Annual Meeting
RTNova systemic platform revealed, enabling ease of administration and ability to target multiple tumor types
Completed public offering of US$6.1 million
SAN DIEGO, May 14, 2024–(BUSINESS WIRE)–Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today released its first quarter 2024 operating and financial results and reviewed highlights of recent deals.
“Calidi’s current focus is on raising additional capital and implementing ongoing cost-cutting measures in order to advance our promising pipeline of novel immunotherapies designed to successfully target and eliminate solid tumors throughout the body. We plan to present three posters at ASCO , including an update on our ongoing study with City of Hope for recurrent high-grade glioma,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. “In parallel with our clinical progress, Calidi has strengthened our preclinical programs through our powerful R&D engine, unveiled our new systemic delivery platform to target diverse tumor types, and executed a capital raise to strengthen our balance sheet. We believe these efforts will help propel the company through important milestones, including an interim clinical update from our ongoing Phase 1 study and the initiation of the Phase 1 study with Northwestern University expected in the third quarter of 2024, subject to funding. of additional capital.”
Q1 2024 and recent corporate developments
-
Announced upcoming poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Posters will include an update on the Phase 1 trial in collaboration with City of Hope for CLD-101 in recurrent high-grade glioma. Additional posters will focus on preclinical data from the company’s RTNova (CLD-400) and CLD-201 platforms.
-
Presented new data at the American Association for Cancer Research (AACR) Annual Meeting supporting the pioneering use of CLD-101 and CLD-201 stem cells to protect and enhance antitumor virotherapies. The results of the experiments, conducted in collaboration with City of Hope, provide further details about the unique stem cell-based mode of delivery and the therapeutic potential at the heart of Calidi’s new technology.
-
He highlighted the company’s new RTNova systemic platform, a targeted enveloped virotherapy, which has pre-clinically demonstrated the ability to resist inactivation by human serum and the ability to target multiple tumor types. This new therapeutic approach has the potential to be available to a diverse population of patients with different forms of cancer, while remaining cost-effective and easy to administer.
-
Closed public offering of 15,197,500 common shares and subscription warrants, with gross proceeds of US$6.1 million.
The story continues
First Quarter 2024 Financial Results
The company reported a net loss of $7.2 million, or 20 cents per share, for the three months ended March 31, 2024, compared to a net loss of $6.5 million, or $0.20 per share. $0.75 per share, in the same period in 2023.
Research and development expenses were $2.7 million for the three months ended March 31, 2024, compared to $2.6 million for the comparable period in 2023, respectively.
General and administrative expenses were $4.0 million for the three months ended March 31, 2024, compared to $2.8 million for the comparable period in 2023, respectively.
The company had approximately $1.2 million in cash and $0.2 million in restricted cash as of March 31, 2024, compared to $1.9 million in cash and $0.2 million in restricted cash on December 31, 2023.
About Calidi Bioterapeutica
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to weaponize the immune system to fight cancer. Calidi’s new stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying oncolytic virus payloads for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s universal, ready-to-use cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses, leading to greater efficacy and improved patient safety. Calidi’s ready-to-use preclinical enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information please visit www.calidibio.com .
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipate”, “believe”, “continue”, “could” , “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “toward” , “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding future important milestones (including the reporting of interim clinical results and patient dosing), planned clinical trials, and statements regarding the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs regarding future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi will not be able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early clinical trial results will not necessarily predict the results finals and that one or more clinical outcomes may change materially following a more comprehensive review of the data, and as more patient data becomes available, the risk increases that Calidi will not receive FDA approval for some or all of its therapeutic candidates . Other risks and uncertainties are set forth in the section titled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Registration Statements filed with the SEC on Form S-4 filed on August 2, 2023, on Form S-1 filed on October 6, 2023, on Form S-1 filed on January 29, 2024, as amended on February 7, 2024, on Form 10-K filed on March 15, 2024, and in the Final Prospectus filed on 17 April 2024.
|
CALIDI BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEET (In thousands, except for nominal value data) (Unaudited) |
||||||||
|
March 31, |
December 31th, |
|||||||
|
ACTIVE |
||||||||
|
CURRENT ASSETS |
||||||||
|
Money |
$ |
1,143 |
$ |
1,949 |
||||
|
Prepaid expenses and other current assets |
793 |
2,354 |
||||||
|
Total current assets |
1,936 |
4,303 |
||||||
|
NON-CURRENT ASSETS |
||||||||
|
Machines and equipment, liquids |
1,165 |
1,270 |
||||||
|
Operating lease right-of-use assets, net |
3,798 |
4,073 |
||||||
|
Other non-current assets |
506 |
373 |
||||||
|
TOTAL ASSETS |
$ |
7,405 |
$ |
10,019 |
||||
|
LIABILITIES AND SHAREHOLDER DEFICIT |
||||||||
|
CURRENT LIABILITIES |
||||||||
|
Bills to pay |
$ |
3,805 |
$ |
2,796 |
||||
|
Accounts payable with related parties |
94 |
81 |
||||||
|
Accumulated expenses and other current liabilities |
4,566 |
4,896 |
||||||
|
Accumulated expenses with related parties and other current liabilities |
536 |
536 |
||||||
|
Term notes payable, net of discount, including accrued interest |
555 |
529 |
||||||
|
Notes payable to related parties, net of discount, including accrued interest |
2,455 |
278 |
||||||
|
Convertible notes payable, including accrued interest |
1,021 |
– |
||||||
|
Related party bridge loan payable, including accrued interest |
205 |
– |
||||||
|
Related party other current liabilities |
567 |
– |
||||||
|
Finance lease liabilities, current |
74 |
81 |
||||||
|
Operating lease right-of-use liabilities, current |
1,075 |
1,035 |
||||||
|
Total current liabilities |
14,953 |
10,232 |
||||||
|
NON-CURRENT LIABILITIES |
||||||||
|
Operating lease right-of-use liabilities, non-current |
2,756 |
3,037 |
||||||
|
Financial lease liabilities, non-current |
197 |
216 |
||||||
|
Convertible notes payable, including accrued interest |
3,375 |
– |
||||||
|
Warranty liability |
647 |
623 |
||||||
|
Related Party Warranty Liability |
50 |
48 |
||||||
|
Notes payable to related parties, net of discount, including accrued interest |
– |
2,060 |
||||||
|
Other non-current liabilities |
– |
2,038 |
||||||
|
TOTAL RESPONSIBILITIES |
21,978 |
18,254 |
||||||
|
SHAREHOLDER DEFICIT |
(14,573 |
) |
(8,235 |
) |
||||
|
TOTAL LIABILITIES AND SHAREHOLDER DEFICIT |
$ |
7,405 |
$ |
10,019 |
||||
|
CALIDI BIOTHERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except data per share) (Unaudited) |
||||||||
|
Three months ending March 31, |
||||||||
|
2024 |
2023 |
|||||||
|
OPERATIONAL EXPENSES |
||||||||
|
Research and Development |
$ |
(2,743 |
) |
$ |
(2,622 |
) |
||
|
General and administrative |
(4,009 |
) |
(2,792 |
) |
||||
|
Total operating expense |
(6,752 |
) |
(5,414 |
) |
||||
|
Loss of operations |
(6,752 |
) |
(5,414 |
) |
||||
|
OTHER REVENUE (EXPENSES), NET |
||||||||
|
Interest Expenses |
(98 |
) |
(67 |
) |
||||
|
Interest expense – related party |
(155 |
) |
(150 |
) |
||||
|
Interest Expenses |
(157 |
) |
(150 |
) |
||||
|
Change in the fair value of debt, other liabilities and derivatives |
(198 |
) |
(1,026 |
) |
||||
|
Change in the fair value of debts, other liabilities and derivatives – related party |
(1 |
) |
(487 |
) |
||||
|
Change in the fair value of debt, other liabilities and derivatives |
(1 |
) |
(487 |
) |
||||
|
Income granted |
– |
691 |
||||||
|
Other expenses, net |
(17 |
) |
(5 |
) |
||||
|
Total other expenses, net |
(469 |
) |
(1,044 |
) |
||||
|
LOSS BEFORE INCOME TAX |
(7,221 |
) |
(6,458 |
) |
||||
|
Provision for income tax |
(4 |
) |
(4 |
) |
||||
|
NET LOSS |
$ |
(7,225 |
) |
$ |
(6,462 |
) |
||
|
Net loss per share; basic and diluted |
$ |
(0.20 |
) |
$ |
(0.75 |
) |
||
|
Weighted average of common shares outstanding; basic and diluted |
35,552 |
8,655 |
||||||
View the original version on businesswire.com: https://www.businesswire.com/news/home/20240514985028/en/
Contacts
For Investors:
Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com
For media:
Stephen Thesing
ir@calidibio.com
The spotlight next week will shift somewhat to the Federal Reserve’s second-quarter earnings season and monetary policy. Market watchers will be treated to results from several major names, including Dow 30 components Goldman Sachs (GS), UnitedHealth (UNH), Johnson & Johnson (JNJ) and American Express (AXP), along with streaming giant Netflix (NFLX).
The Fed will still attract some attention as investors will be eager to hear from a packed lineup of central bank speakers just before the policy meeting lockout period.
In terms of the economic calendar, after fifteen days of labor market and inflation indicators, activity data will gain momentum in the form of the latest retail sales and industrial production reports.
Earnings Highlight: Monday, July 15 – Goldman Sachs (GS) and BlackRock (Black). See the full earnings calendar.
Earnings Highlight: Tuesday, July 16 – UnitedHealth (UNH), Bank of America (BAC), Progressive (PGR), Morgan Stanley (IN), PNC Financial (PNC) and JB Hunt Transport (JBHT). See the full earnings calendar.
Earnings Highlight: Wednesday, July 17 – Johnson & Johnson (JNJ), US Bancorp (USB), Morgan Children (KMI), United Airlines (UAL) and Ally Financial (ALLY). See the full earnings calendar.
Earnings Highlight: Thursday, July 18 – Netflix (NFLX), Abbott Laboratories (ABT), Black stone (BX), Domino’s pizza (ZDP) and Taiwan Semiconductor Manufacturing (TSM). See the full earnings calendar.
Earnings Highlight: Friday, July 19 – American Express (AXP), Halliburton (THANKS) and Travelers (VRT (return to recoverable value)) See the full earnings calendar.
IPO Observation: Hospital and healthcare clinic operator Ardent Health Partners (TARDT), insurance service provider Twfg (TWFG) and the biotechnology company Lirum Therapeutics (LRTX) are expected to price their IPOs and begin trading next week. The analyst quiet period ends at Rectitude (RECT) to free up analysts to publish ratings.
Police cars outside the residence of Thomas Matthew Crooks, the suspected shooter at a Trump rally on Saturday, investigate the area in Pennsylvania. Following the incident, one rally attendee was killed, two rally attendees are in critical condition and Donald Trump suffered a non-fatal gunshot wound. The shooter is dead after being shot dead by the United States Secret Service. (Photo by Kyle Mazza/Anadolu via Getty Images)
Investors will initially favor traditional safe-haven assets and may lean toward trades more closely tied to former President Donald Trump’s chances of winning the White House after he survived an assassination attempt, according to market watchers.
“There will undoubtedly be some protectionist or safe-haven flows into Asia early this morning,” said Nick Twidale, chief market analyst at ATFX Global Markets. “I suspect gold could test all-time highs, we’ll see the yen being bought and the dollar, and flows into Treasuries as well.”
Early market commentary suggested Trump’s shooting at a rally in Pennsylvania on Saturday could also prompt traders to increase his likelihood of success in the November election. His support for looser fiscal policy and higher tariffs is generally seen as likely to benefit the dollar and weaken Treasuries.
An indicator of market sentiment heading into the weekend: Bitcoin surged above $60,000, likely reflecting Trump’s pro-crypto stance.
Other assets positively linked to the so-called Trump trade include stocks of energy companies, private prisons, credit card companies and health insurers.
Traders will also be closely watching market measures of expected volatility on Monday, such as those in the tariff-sensitive Chinese yuan and Mexican peso, which have begun to price in the U.S. vote.
Trump said he was shot in the right ear after a shooting at his rally. His campaign said in a statement that he was “fine” after the incident, which prompted him to rush off the stage.
“Currencies will be the first major market on Monday in Asia to react to the weekend’s shots. There’s potential for extra volatility, and getting a clear reading could be especially difficult because liquidity will be hurt by Japan’s national holiday,” said Garfield Reynolds, Asia team leader for Bloomberg Markets Live.
Strategists had already expected a volatile run-up to the election, particularly as Democrats are still agonizing over President Joe Biden’s candidacy after his poor performance in last month’s debate raised questions about his age. Investors were also grappling with the possibility that the election could end in a drawn-out dispute or political violence.
But there is little precedent for events like those in Pennsylvania. When President Ronald Reagan was shot four decades ago, the stock market plunged before closing early. The next day, March 31, 1981, the S&P 500 rose more than 1% and benchmark 10-year Treasury yields fell 9 basis points to 13.13%, according to data compiled by Bloomberg.
Bond investors should pay particular attention as the attack is likely to boost Trump’s election chances and ultimately lead to concerns about the fiscal outlook, according to Marko Papic, chief strategist at California-based BCA Research Inc.
“The bond market must at some point become aware of President Trump’s greater chances of winning the White House than any of his rivals,” Papic wrote. “And I continue to believe that as his chances increase, so too must the likelihood of a bond market revolt.”
Kyle Rodda, senior financial markets analyst at Capital.com, said he was seeing client flows into Bitcoin and gold following the shooting.
“This news marks a turning point in American policy norms,” he said. “For markets, it means safe-haven trades, but more tilted toward non-traditional safe-havens.”
Follow us for stories on Bill Gates, Elon Musk, Mukesh Ambani, Gautam Adani as we bring you everything that’s happening in the business world. Follow the latest gold and silver prices here too. Stay in the know on all things business with us.
Latest news on July 11, 2024: Airtel says its new Xstream Fiber plans bundle over 350 live TV channels (Official Photo) (Reuters) Disclaimer: This is an AI-generated live blog and has not been edited by Hindustan Times staff.
Follow all the updates here:
-
Thu, 11 Jul 2024 08:44 PM
Business News LIVE Updates: Decoding Airtel’s new Xstream Fiber packages, finding value with Live TV and OTT
- Airtel confirms to HT that the live TV proposition is being delivered using its DTH network, while the bundled streaming subscriptions are an extension of its Xstream Play platform.
-
Thu, 11 Jul 2024 03:58 PM
Business News LIVE Updates: TCS Q1 results meet estimates: Net profit up 9%, ₹10 dividend declared
- TCS’s consolidated revenue rose 5.4% to Rs 626.13 billion in the June quarter. Analysts had expected revenue of Rs 622.07 billion, as per LSEG data.
-
Thu, 11 Jul 2024 03:51 PM
Business News LIVE Updates: Indian companies falsified generic Viagra data to get approval, says US FDA: Report
- Synapse Labs Pvt. Ltd may have been used in hundreds of drugs that are still available for sale, the report said.
-
Thu, 11 Jul 2024 03:09 PM
LIVE Business News Updates: Namita Thapar’s emotional post on Emcure IPO listing: ‘Mirza Ghalib sums up my feelings’
- Emcure Pharmaceuticals was listed at ₹1,325.05, up 31.45% on the BSE and NSE on July 10.
-
Thu, 11 Jul 2024 02:39 PM
LIVE business news updates: Amazon could face investigation over treatment of UK food suppliers, watchdog says
- An Amazon spokesperson said the company has made several improvements for food suppliers since last year’s results.
-
Thu, 11 Jul 2024 01:39 PM
LIVE Business News Updates: This Bengaluru company aims to launch a ‘space habitat’ by 2027, in talks with SpaceX
- AkashaLabdhi calls itself a “home among the stars” as it says the company’s area of expertise is signal processing and continuous automation.
-
Thu, 11 Jul 2024 01:10 PM
Business News LIVE Updates: Amazon India employees on working conditions: Made to stand for hours, bathroom breaks not allowed
- A survey conducted by UNI Global Union with the Amazon India Workers Association had 1,838 participants who alleged appalling working conditions at Amazon facilities in India.
-
Thu, 11 Jul 2024 12:44 PM
LIVE Business News Updates: UK overhauls listing rules in bid to attract IPOs to London: What has changed?
- The new rules allow companies to carry out more activities without putting them to a shareholder vote, the UK’s Financial Conduct Authority said.
-
Thu, 11 Jul 2024 12:18 PM
Business News LIVE Updates: Want to send money abroad? Open foreign currency accounts at GIFT City
- Foreign currency accounts will be like a bank account in India, but instead of rupees, you hold foreign currency like US dollars.
-
Thu, 11 Jul 2024 11:30 AM
Business News LIVE Updates: First Abu Dhabi Bank denies interest in acquiring stake in Yes Bank: Report
- The report said the Yes Bank stake sale has attracted interest from Japan, including Mitsubishi UFJ Financial Group Inc. and Sumitomo Mitsui Financial Group Inc.
-
Thu, 11 Jul 2024 11:04 AM
LIVE Business News Updates: TCS Share Price Surges Ahead of Q1 Results: What Brokers Say About the Stock
- TCS Share Price: The stock opened at ₹3,944.65 against its previous close of ₹3,909.90. It then rose 1.8 percent to ₹3,979.90 level.
-
Thu, 11 Jul 2024 10:22 AM
LIVE Business News Updates: Reliance Jio IPO listing likely in 2025 at $112 billion valuation: Jefferies
- Jio “could list at a valuation of $112 billion” and add “7-15 percent upside” to Reliance Industries’ share price, Jefferies said.
-
Thu, 11 Jul 2024 09:42 AM
LIVE Business News Updates: Yes Bank shares rise after Moody’s revises outlook to ‘positive’ from ‘stable’
- Global rating agency Moody’s has raised its outlook on Yes Bank to positive from “stable” despite expectations of a gradual improvement in its depositor base.
-
Thu, 11 Jul 2024 09:16 AM
Business News LIVE Updates: Sahaj Solar IPO opens today: All you need to know before subscribing to the issue
- Sahaj Solar IPO: The block issue aims to raise ₹52.56 crore through issuance of 2.92 million new shares and will close on July 15.
-
Thu, 11 Jul 2024 08:40 AM
LIVE Business News Updates: Why Analysts Believe India’s Earnings Season May Disappoint Stock Market Investors
- Investors in Indian stocks hoping for a robust earnings season to justify expensive valuations are likely to be disappointed.
-
Thu, 11 Jul 2024 08:35 AM
LIVE Business News Updates: Elon Musk Says Second Neuralink Brain Implant Will ‘Give People Superpowers’ Within a Week
- Elon Musk said Neuralink will make some changes to try to alleviate the problem of its electrode wires retracting from brain tissue.
-
Thu, 11 Jul 2024 07:59 AM
LIVE Business News Updates: Apple warns Indian iPhone users of possible Pegasus-like ‘spyware attack’
- In April this year, the Indian Computer Emergency Response Team (Cert-In) flagged several vulnerabilities in Apple’s operating system for iPhone and iPad.
-
Thu, 11 Jul 2024 07:45 AM
Business News LIVE Updates: US stock markets at record highs led by world’s biggest tech companies
- The Philadelphia Semiconductor Index rose 2.4% to a record high after Taiwan Semiconductor Manufacturing Co. reported strong quarterly revenue.
{{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}
{{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}
{{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}
{{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}
{{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}
{{^userSubscribed}} {{/userSubscribed}} {{^userSubscribed}} {{/userSubscribed}}
News / Business / Latest Business News Live Updates Today, July 11, 2024
Source
News
Jio Financial share price: Should you buy this Reliance group stock on Monday ahead of Q1 FY2024 results?
Q1 2024 Results: Jio Financial Share Price will be in focus on Monday as the Reliance Group company has a fixed board meeting on July 15, 2024 to consider and approve the company’s unaudited standalone and consolidated financial results. Trust Group company informed about the Q1 2024 Results date on Wednesday last week via an exchange filing. According to stock market experts, Jio Financial Services Limited is poised to deliver impressive Q1 results for FY25 on solid operating income. They have forecast a healthy QoQ PAT for the company in Q1 FY25.
Jio Financial Services News
Speaking on the Jio Financial Services Q1 2024 results, Manish Chowdhury, Head of Research, StoxBox, said, “We believe Jio Financial Services is poised to deliver impressive results in Q1FY25 aided by its operating income, which is likely to show robust growth driven by strong investment income, which in turn should lead to healthy PAT growth on a sequential basis. Jio Financial Services continues to make strategic moves such as launching digital products and expanding its ecosystem, with a clear focus on future growth. The company has announced plans to introduce products for lending against stocks and mutual funds, leveraging Jio’s large user base, which could be a significant growth driver in the coming quarters.”
“Furthermore, with the NBFC receiving RBI approval to become a primary investment company, Jio Financial Services is well-positioned to unlock value from its investments. Overall, we expect the company to report robust numbers in the upcoming quarter,” the StoxBox expert added.
Jio Financial Stock Target Price
Speaking about the technical outlook of Jio Financial share price, Ganesh Dongre, Senior Manager, Technical Research at Anand Rathi, said, “Jio Financial Services share price is poised to make a fresh high at the ₹260 apiece level. If the stock breaks above this mark, the Reliance Group stock could make a fresh high by touching the ₹290-₹295 zone. Hence, those with Jio Finance stock in their portfolio are advised to stick to the script by keeping a stop loss at ₹205. If the stock breaks above ₹260 decisively, then one can upgrade the stop loss at ₹240 for the near-term target of ₹295.”
On the advice to new buyers regarding Jio Financial stock, Ganesh Dongre said, “New buyers are advised to wait for the breakout. Once the stock breaks above ₹260, one can buy this Reliance Group stock at the short term target of ₹295, keeping a stop loss of ₹240 apiece.”
Disclaimer: The views and recommendations made above are those of individual analysts or brokerage firms, and not of Mint. Investors are advised to consult with certified experts before making any investment decisions.
3.6 Crore Indians visited in a single day choosing us as India’s undisputed platform for General Election Results. Explore Latest Updates here!
Topics that may interest you
Larry Lepard – The impending bubble burst will be absolutely huge for Bitcoin
“You Only Need 0.02 BTC to Retire Forever – Here’s Why” – Willy Woo
Inside the Banana Zone: The Cryptocurrency Trend Everyone’s Talking About – Raoul Pal
DIGITAL BLOCK! You Live in a Virtual Prison Without Knowing It: The 2025 WARNING by Whitney Webb
“Many Bitcoin Investors Will Be Multimillionaires Before 2030” – Michael Saylor
Switchboard Revolutionizes DeFi with New Oracle Aggregator
Fintech unicorn Zeta launches credit as a UPI-linked service for banks
👀 Lido prepares its response to the recovery boom
Latest Business News Live Updates Today, July 11, 2024
Is Zypto Wallet a Reliable Choice for DeFi Users?
Larry Lepard – The impending bubble burst will be absolutely huge for Bitcoin
“You Only Need 0.02 BTC to Retire Forever – Here’s Why” – Willy Woo
Inside the Banana Zone: The Cryptocurrency Trend Everyone’s Talking About – Raoul Pal
DIGITAL BLOCK! You Live in a Virtual Prison Without Knowing It: The 2025 WARNING by Whitney Webb
“Many Bitcoin Investors Will Be Multimillionaires Before 2030” – Michael Saylor
-
DeFi6 months agoSwitchboard Revolutionizes DeFi with New Oracle Aggregator
-
Fintech9 months agoFintech unicorn Zeta launches credit as a UPI-linked service for banks
-
DeFi8 months ago👀 Lido prepares its response to the recovery boom
-
News6 months agoLatest Business News Live Updates Today, July 11, 2024
-
DeFi6 months agoIs Zypto Wallet a Reliable Choice for DeFi Users?
-
Fintech6 months agoFinTech LIVE New York: Mastercard and the Power of Partnership
-
News8 months agoSalesforce Q1 2025 Earnings Report (CRM)
-
DeFi6 months agoEthena downplays danger of letting traders use USDe to back risky bets – DL News
-
News8 months agoThink Finance Loan Repayment Scam Victims to Get $384 Million
-
ETFs9 months agoGold ETFs see first outing after March 2023 at ₹396 cr on profit booking
-
Videos8 months ago“We will enter the ‘banana zone’ in 2 WEEKS! Cryptocurrency prices will quadruple!” – Raoul Pal
-
Videos9 months agoPREPARE! Millions of People Will Buy Bitcoin When the “ULTIMATE COLLAPSE” Begins in 2024 – Larry Lepard